Related Experiment Video

Updated: Jun 19, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a

J Ma1, W Yang, N Fang

  • 1Department of Cardiology, Shanghai 6th People's Hospital, Shanghai Jiao tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China.

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|October 13, 2009
PubMed

Insights

For type 2 diabetes, targeting an HbA1c below 7.0% offers no macrovascular benefit and increases hypoglycemia risk. A target of 7.0-7.9% shows microvascular benefits without increased hypoglycemia.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Diabetes Research

Background:

  • The link between lowering glycated hemoglobin (HbA1c) and macrovascular complications in type 2 diabetes is unclear, making HbA1c targets controversial.
  • Intensive glycemic control aims to reduce diabetes-related complications but carries risks.

Purpose of the Study:

  • To evaluate the impact of intensive versus standard glycemic control on macrovascular and microvascular complications in type 2 diabetes mellitus.
  • To determine optimal glycated hemoglobin (HbA1c) targets for managing vascular events.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials comparing intensive and standard glycemic control.
  • Primary endpoint: combined macrovascular complications (cardiac events, stroke, peripheral vascular disease).
  • Analysis using fixed and random effect models.

Main Results:

  • Intensive glycemic control targeting HbA1c <7.0% showed no benefit for macrovascular or microvascular complications and increased severe hypoglycemia risk (P<0.00001).
  • Intensive glycemic control targeting HbA1c 7.0-7.9% reduced microvascular events (P<0.05) without increasing hypoglycemia (P=0.74), but did not impact macrovascular complications (P>0.1).

Conclusions:

  • A target HbA1c level of 7.0-7.9% appears more beneficial than <7.0% for patients with established type 2 diabetes.
  • This target range may offer a better balance between microvascular benefits and hypoglycemia risk.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...